Spyre Therapeutics, Inc. (SYRE) Investment Analysis:
1. Executive Summary:
Spyre Therapeutics, Inc. (SYRE) operates as a clinical-stage biotechnology firm dedicated to the engineering and advancement of a sophisticated pipeline of antibodies aimed at treating inflammatory bowel disease (IBD) and diverse immune-mediated conditions.[1, 2] The corporate strategy centers on the "bio-better" approach, wherein the company identifies biologically validated pathways—such as those targeted by existing multi-billion-dollar blockbusters—and utilizes advanced antibody engineering to enhance their potency, half-life, and delivery mechanisms.[2, 3] The organization primarily targets the large and expanding global markets for Ulcerative Colitis (UC) and Crohn’s Disease (CD), while recently expanding its scope into rheumatological indications like Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).[2, 4]
As a development-stage entity, Spyre does not currently generate product revenue.[5, 6] Its economic architecture is built upon the prospective commercialization of its lead investigational assets: SPY001 (anti-$\alpha4\beta7$), SPY002 (anti-TL1A), and SPY003 (anti-IL-23), alongside several rational combination products.[2, 7] The company's geographical focus is predominantly centered on high-value pharmaceutical markets including North America, the European Union, and Japan, where the prevalence of autoimmune disorders is highest and reimbursement environments for innovative biologics are most robust.[8, 9] Primary customers are anticipated to be specialized gastroenterologists and rheumatologists who prescribe advanced therapies, supported by a payer landscape that includes private insurers and government health programs.[10, 11]
The core products of Spyre are distinguished by their utilization of YTE half-life extension technology, which facilitates a transition from frequent hospital-based infusions to highly convenient subcutaneous injections administered as infrequently as every three to six months.[2, 12] This shift addresses a critical unmet need in chronic disease management: treatment adherence. Patients and clinicians are incentivized to choose Spyre’s candidates over established alternatives due to the promise of superior clinical efficacy—specifically deeper histopathological remission—and a drastically reduced treatment burden.[2, 13] By co-formulating these antibodies into single-injector combinations, Spyre seeks to transcend the "therapeutic ceiling" of current monotherapies, offering a value proposition based on deep and durable disease control.[3, 7] TRANSFORMATIVE BIOLOGICAL ENGINEERING.
2. Business Drivers & Strategic Overview:
The strategic viability of Spyre Therapeutics rests upon its ability to execute a "fast-follower" strategy with "best-in-class" optimization. Rather than assuming the high-risk burden of discovering novel biological targets, Spyre focuses on pathways that have already been clinically and commercially de-risked by industry incumbents.[2, 14] The primary revenue drivers for the company in the long term will be the successful clinical readout of its Phase 2 and Phase 3 trials, the subsequent regulatory approval of its monotherapy and combination programs, and the capture of significant market share from first-generation biologics.[3, 4]
Product and Service Detail
The Spyre portfolio is meticulously organized around three pillars of immunology, each addressing a distinct but complementary mechanism of action (MOA) within the inflammatory cascade.
- SPY001 (Anti-$\alpha4\beta7$): This monoclonal antibody targets the $\alpha4\beta7$ integrin, a cell-surface protein that governs the migration of leukocytes specifically to the gastrointestinal tract.[2, 7] By inhibiting this interaction, SPY001 prevents the recruitment of pro-inflammatory cells to the gut lining. While it shares an epitope with Takeda’s vedolizumab (Entyvio), SPY001 is engineered to have a half-life of approximately 90 days, supporting potential twice-annual dosing.[13, 14] Recent Phase 2 SKYLINE-UC data showed a 40% clinical remission rate at 12 weeks, which compares favorably to historical data for Entyvio.[7, 15]
- SPY002 (Anti-TL1A): Tumor Necrosis Factor-like Ligand 1A (TL1A) has emerged as one of the most valuable targets in IBD due to its dual role in promoting both inflammation and tissue fibrosis.[2, 16] SPY002 is designed to neutralize TL1A with high potency and a similarly extended half-life.[2, 17] This program is central to Spyre's precision medicine strategy, as TL1A inhibition has shown particular efficacy in patients with specific genetic biomarkers.[9, 18]
- SPY003 (Anti-IL-23): Targeting the p19 subunit of Interleukin-23, this antibody addresses a cytokine that is essential for the differentiation and maintenance of Th17 cells.[2] The IL-23 pathway is already validated by blockbuster drugs like AbbVie’s Skyrizi, and Spyre’s version aims to provide a more durable and convenient alternative.[2, 19]
- Rational Combinations (SPY120, SPY130, SPY230): The most innovative aspect of Spyre’s strategy is the co-formulation of these antibodies.[2] SPY120 combines the gut-selective blockade of SPY001 with the anti-fibrotic potential of SPY002.[2, 3] Preclinical data suggests that these combinations may offer additive efficacy, potentially providing a solution for the significant portion of IBD patients who fail to respond to current monotherapies.[2, 13]
Moat Analysis: Barriers to Entry and Sustained Advantage
Spyre is building a multi-layered moat designed to protect its future market position from both biosimilar erosion and new competitive entries.
- Intellectual Property and Proprietary Engineering: The company’s use of YTE (M252Y/S254T/T256E) mutations in the Fc region of its antibodies constitutes a significant technical barrier.[2, 14] This engineering increases the affinity of the antibody for the neonatal Fc receptor (FcRn), allowing for enhanced recycling and a half-life that is three to four times longer than standard IgG antibodies.[2, 3] This "extended-stay" biology is protected by a robust portfolio of composition-of-matter and method-of-use patents.
- Management and "Meritocratic" Pedigree: The company’s leadership team includes several former executives from Prometheus Biosciences, the firm that pioneered TL1A targeting before being acquired by Merck for $10.8 billion.[20, 21] This provides Spyre with a localized "network effect" of scientific expertise and institutional knowledge regarding the TL1A pathway and IBD trial design that is difficult for competitors to replicate.[22, 23]
- Manufacturing and Formulation Scale: Spyre has invested heavily in high-concentration subcutaneous formulations.[2] Delivering a combination of two different antibodies in a single, small-volume autoinjector is a significant engineering challenge.[3] By solving these "CMC" (Chemistry, Manufacturing, and Controls) hurdles early, Spyre creates a convenience moat that hospital-administered infusions cannot cross.[2, 12]
- Ecosystem Advantage: By developing a "platform" trial (SKYLINE), Spyre can test multiple candidates against a shared placebo arm, accelerating development timelines and reducing the cost per data point compared to traditional serial clinical trials.[4, 24]
TAM / Market Opportunity Analysis
The total addressable market (TAM) for Spyre is immense, reflecting the global burden of autoimmune inflammatory diseases.
| Market Segment |
2025/2026 Size Est. |
2034/2035 Forecast |
Projected CAGR |
Source |
| Global IBD Market |
$31.24B (2026) |
$41.64B (2034) |
3.66% |
[8] |
| Ulcerative Colitis (UC) |
$8.70B (2026) |
$14.50B (2035) |
5.80% |
[10] |
| Crohn's Disease (CD) |
$14.40B (2026) |
$19.20B (2033) |
4.20% |
[11] |
| IBD Biologics Market |
$60.73B (2026) |
$130.81B (2036) |
8.00% |
[25] |
| Rheumatoid Arthritis (RA) |
High [2] |
High [4] |
Moderate |
[2] |
The IBD biologics segment is expected to grow at a faster rate (8.0%) than the general IBD market (3.66%) as patients shift from conventional steroids and immunosuppressants to targeted therapies.[8, 25] North America remains the most important end market, accounting for approximately 59% of global revenue in some segments.[26]
Competitive Landscape
Spyre operates in an environment characterized by "Red Queen" competition, where constant innovation is required just to maintain a relative position.
- Takeda Pharmaceutical (Entyvio/Vedolizumab): As the incumbent in the anti-$\alpha4\beta7$ space, Entyvio is the primary target for SPY001. Entyvio is a blockbuster with projected peak sales of $6.9 billion in 2030.[13] However, its need for frequent dosing (every 8 weeks for IV) leaves it vulnerable to Spyre’s long-acting subcutaneous alternative.[13, 19]
- Merck & Co. (Tulisokibart/MK-7240): Following the Prometheus acquisition, Merck is the frontrunner in the TL1A class with Tulisokibart currently in Phase 3.[9, 27] In Phase 2, Tulisokibart showed a 26% clinical remission rate.[28] Spyre’s SPY002 aims to match this efficacy while offering superior dosing convenience and potentially better potency through advanced engineering.[2, 14]
- Roche/Genentech (Afimkibart/RG6631): Roche entered the TL1A fray by acquiring Telavant from Roivant for $7 billion.[16, 29] Afimkibart is another potent anti-TL1A antibody in Phase 3 development.[16, 30]
- Teva/Sanofi (Duvakitug/TEV-574): This anti-TL1A partnership is also moving into Phase 3.[27, 31] Duvakitug has demonstrated durable clinical and endoscopic efficacy through 44 weeks, with analysts projecting €1 billion in sales by 2032.[27]
Currently, Spyre is gaining ground on the strength of its SPY001 clinical results, which numerically outperformed the historical "therapeutic ceiling" associated with $\alpha4\beta7$ blockers.[13, 15] The company's unique focus on combination therapy provides a strategic "off-ramp" from the crowded monotherapy market. ENGINEERED FOR SUPREMACY.
3. Financial Performance & Valuation:
Analyzing Spyre Therapeutics requires a shift away from traditional earnings-per-share (EPS) metrics toward an evaluation of clinical milestones as the primary currency of value.
Latest Annual and Quarterly Financial Performance
- Latest Reported Fiscal Year: 2025 (ended December 31, 2025).[17, 32]
- Latest Reported Fiscal Quarter: Fourth Quarter 2025 (ended December 31, 2025).[17, 33]
- Announcement Date: February 19, 2026.[32, 33]
Income Statement Analysis:
Spyre reported a net loss of $62.5 million for the fourth quarter of 2025, a slight increase from the $56.3 million loss in the same period of 2024.[17, 33] This performance was largely in line with expectations for a clinical-stage company scaling its operations.
| Metric (Q4 2025) |
Value |
Comparison (Q4 2024) |
Primary Driver |
| Revenue |
$0 |
$0 |
Pre-revenue clinical status [5] |
| R&D Expense |
$44.6M |
$50.5M |
Lower early-stage R&D; higher trial costs [17] |
| G&A Expense |
$12.5M |
$10.8M |
Increased headcount/professional fees [17] |
| Other Exp/Inc |
($5.4M) |
$5.0M |
Fair value change in CVR liability [17] |
| Net Loss |
$62.5M |
$56.3M |
Scaling of Phase 2 trials [33] |
| Reported EPS |
($0.70) |
N/A |
Missed consensus of ($0.66) by $0.04 [34, 35] |
Balance Sheet and Cash Flow:
As of December 31, 2025, the company held $756.5 million in cash, cash equivalents, and marketable securities.[17, 33] However, the most significant financial event occurred on April 16, 2026, when Spyre closed an upsized public offering of 7,475,000 shares at $62.00 per share, generating gross proceeds of $463.5 million.[1, 36] This brings the company's pro-forma cash position to approximately $1.2 billion, extending the anticipated cash runway into the second half of 2028.[17, 33]
Management Commentary and Guidance
On the latest earnings call, management emphasized the transition to a "catalyst-rich" 2026.[4, 6] CEO Cameron Turtle highlighted that enrollment in the SKYLINE-UC Part A trial was completed ahead of schedule, allowing the company to accelerate its data readouts.[4] While formal financial guidance was not provided, the "6 in '26" strategy—six proof-of-concept readouts across two platforms—remains the key operational benchmark for investors.[4, 6] The appointment of Kate Tansey Chevlen as Chief Commercial Officer was presented as a signal that the company is beginning Phase 3 readiness and commercial planning.[4]
Market Reaction and Analyst Sentiment
The April 13, 2026, announcement of positive SPY001 induction results had a massive impact on the stock price and analyst valuations. Shares surged nearly 30% in a single session to $66.50.[13, 37]
| Analyst Firm |
New Price Target |
Previous Target |
Action Date |
Rationale |
| Leerink Partners |
$106.00 |
N/A |
April 2026 |
Potential "best-in-class" profile [37, 38] |
| BTIG |
$98.00 |
$70.00 |
April 2026 |
De-risking of $\alpha4\beta7$ backbone [15, 39] |
| Stifel |
$92.00 |
$70.00 |
March 2026 |
Bullish on TL1A and IBD platform [34, 35] |
| Jefferies |
$85.00 |
$47.00 |
April 2026 |
Numerical improvement over Entyvio [15] |
| Wells Fargo |
$90.00 |
$50.00 |
April 2026 |
Support for Q3M/Q6M dosing [39, 40] |
Financial Drivers of Valuation
The valuation of SYRE is fundamentally tied to the rNPV (risk-adjusted Net Present Value) of its pipeline. The key assumptions driving this model include:
- Market Share of IBD Biologics: Entyvio’s $6.9B peak sales serves as the benchmark.[13] SPY001 is modeled to capture 15-20% of this segment by year five post-launch.
- Pricing and Gross Margins: As a premium biologic, SPY001 is expected to be priced at $30,000 to $50,000 per patient per year, with gross margins exceeding 85% typical of the industry.[8, 10]
- Combination Synergy: If SPY120 (combination) can double remission rates, it would potentially command a price premium or higher market penetration, significantly boosting the valuation floor.
- Capital Efficiency: The current $1.2B cash pile minimizes the risk of distressed equity financing before 2028, reducing the "dilution discount" applied to the share price.[17, 33]
LIQUIDITY DRIVEN OPTIMISM.
4. Risk Assessment & Macroeconomic Considerations:
Spyre Therapeutics exists in a high-beta, high-reward segment of the biotechnology market. The risks are varied, ranging from biological failure to structural market shifts.
Company-Specific Execution Risks
The most immediate risk is clinical failure. While the 12-week induction data for SPY001 was positive, many IBD drugs fail to show sustained efficacy in 52-week maintenance trials.[7, 13] Furthermore, there is the risk of immunogenicity. Some analysts have raised concerns that engineered antibodies can lead to high rates of anti-drug antibodies (ADAs), which could neutralize the drug or cause hypersensitivity reactions.[12] If SPY001 or SPY002 exhibits ADAs in larger patient cohorts, the convenience and efficacy narrative would be severely damaged.
Competitive Risks and Industry Structure
The IBD market is becoming increasingly commoditized by biosimilars and oral small molecules like JAK inhibitors.[10, 41] Spyre faces a "rebate wall" risk, where large incumbents (AbbVie, J&J) use their broad portfolios to offer massive rebates to insurers in exchange for exclusive formulary placement, making it difficult for a small player like Spyre to gain traction.[9] Additionally, the TL1A space is highly congested; if Merck or Roche launches a year ahead of Spyre, they may capture the "prescriber inertia" that is difficult to break.[16, 27]
Regulatory and Legal Risks
Spyre is navigating a complex regulatory environment. The FDA may require more stringent safety data for combination products than for monotherapies, potentially delaying the launch of SPY120.[14, 42] There is also the risk of intellectual property litigation. While Spyre believes its YTE engineering is proprietary, incumbents may challenge these patents to protect their franchises.[2, 3]
Balance Sheet and Capital Allocation Risks
Biotech development is capital-intensive. Although Spyre has ~$1.2B, the simultaneous advancement of six programs could lead to a rapid burn rate.[2, 4] The April 2026 offering led to a 43.1% dilution of existing shareholders over the past year.[43] Continued dilution remains a risk if the company chooses to build a full commercial sales force rather than seeking a partner.
Macroeconomic Sensitivities
- Interest Rate Environment: Pre-revenue biotech valuations are highly sensitive to the discount rate. Prolonged high interest rates would likely suppress the SYRE valuation regardless of clinical success.[6, 44]
- Healthcare Policy: U.S. legislation (e.g., the Inflation Reduction Act) that allows for Medicare price negotiations could impact the long-term peak sales potential of IBD biologics, particularly for chronic therapies with large patient populations.[9, 16]
Warning Signs and Critical Failures
- Early Warning Sign: Higher-than-expected ADA (anti-drug antibody) rates in the SPY002 Phase 1/2 readout or any serious adverse events (SAEs) that are deemed drug-related.[2, 7]
- Damage to Long-Term Thesis: A Phase 3 trial result where SPY001 fails to show statistical significance over placebo in Crohn's disease, or a regulatory decision to deny approval for the subcutaneous combination injector.[14, 24]
HIGH-STAKES BIOLOGICAL PIVOT.
5. 5-Year Scenario Analysis:
This analysis projects the total return for SYRE through early 2031, based on the fundamental drivers of the IBD market and the company's specific pipeline progress.
High Case: The "Blockbuster Acquisition" Scenario (25% Probability)
In this scenario, SPY001 and SPY120 (the combination) achieve clinical data that is not just "best-in-class" but "transformational," showing clinical remission rates >50% in refractory patients.[2, 7] The Q6M (twice-annual) dosing is successfully validated.
* Year 5 Scale: SPY001/SPY120 launch is imminent or underway with $2.5B+ peak sales potential.
* Valuation Assumption: Acquisition at a significant premium by a major pharma player like Sanofi or Merck to consolidate the TL1A/$\alpha4\beta7$ market.
* Exit Multiple: 8x Price/Sales multiple.
* Projected Share Price: $245.00.
Base Case: Successful Monotherapy Launch (50% Probability)
SPY001 and SPY002 successfully navigate Phase 3 and receive FDA approval. SPY001 captures 15% of the anti-integrin market, providing a highly profitable "bio-better" alternative to Entyvio.[10, 13] The combination products are in late-stage Phase 3.
* Year 5 Scale: $1.1B in annualized revenue (initial launch ramp).
* Valuation Assumption: Independence with a specialty sales force or a high-royalty partnership.
* Exit Multiple: 6x Price/Sales multiple.
* Projected Share Price: $85.00.
Low Case: Clinical Setback or Crowded Market (25% Probability)
SPY001 is approved but struggles to gain market share due to the "rebate wall" and competition from cheap biosimilars and oral JAKs.[9] SPY002 (TL1A) fails to differentiate sufficiently from Merck and Roche’s already-marketed products.
* Year 5 Scale: $200M in revenue.
* Valuation Assumption: Low-growth biotech multiple or "broken IPO" valuation.
* Exit Multiple: 2x Price/Sales multiple or cash value.
* Projected Share Price: $12.00.
5-Year Share Price Trajectory and Returns
| Scenario |
Rev (Year 5) |
Margin Assumption |
P/S Multiple |
Current Price |
Implied Price |
Total Return |
Annualized |
Probability |
| High |
$2,500M |
45% (Net) |
8x |
$73.39 |
$245.00 |
+233.8% |
27.2% |
0.25 |
| Base |
$1,100M |
30% (Net) |
6x |
$73.39 |
$85.00 |
+15.8% |
3.0% |
0.50 |
| Low |
$200M |
-20% (Net) |
2x |
$73.39 |
$12.00 |
-83.6% |
-30.3% |
0.25 |
| Weighted |
$1,225M |
23% |
5.5x |
$73.39 |
$106.75 |
+45.5% |
7.8% |
1.00 |
BINARY POTENTIAL UNLOCKED.
6. Qualitative Scorecard:
Each metric is scored on a scale of 1–10 based on current fundamental analysis.
- Management Alignment: 9/10
Leadership includes the architects of the Prometheus exit, providing unparalleled domain expertise.[20, 21] CEO Cameron Turtle owns shares valued at ~$43M, aligning him with long-term equity growth.[45]
- Revenue Quality: 1/10
Non-existent at present; high risk of total loss if clinical trials fail.[5, 6]
- Market Position: 7/10
Gaining share of mind and market "hype" through strong Phase 2 data prints that challenge the therapeutic ceiling of incumbents.[13, 15]
- Growth Outlook: 9/10
Robust, with multiple readouts in 2026 and an expansion strategy into rheumatic diseases like RA and PsA.[2, 4]
- Financial Health: 8/10
Exceptional liquidity with ~$1.2B in pro-forma cash, providing a multi-year buffer against market volatility.[17, 33]
- Business Viability: 6/10
The "bio-better" model is sound, but the execution risk of delivering complex co-formulations in a single injector remains a technical hurdle.[2, 3]
- Capital Allocation: 7/10
Opportunistic and aggressive. The company raised capital immediately following positive data, diluting shareholders but ensuring project funding for the next three years.[1, 36]
- Analyst Sentiment: 9/10
Consensus "Strong Buy" with a wave of price target upgrades following the SPY001 readout.[37, 38, 46]
- Profitability: 1/10
Significant cash burn with no path to profitability until at least 2029.[5, 6]
- Track Record: 8/10
The stock has outperformed 98% of the market over the past year, reflecting high investor confidence in the post-merger pivot.[6, 47]
OVERALL BLENDED SCORE: 6.1 / 10
CLINICAL SUCCESS DEPENDENT.
7. Conclusion & Investment Thesis:
Spyre Therapeutics represents a high-conviction opportunity within the immunology and inflammation (I&I) space, predicated on the successful re-engineering of the IBD therapeutic paradigm. The company’s core thesis—that extended half-life antibodies and rational combinations can deliver superior convenience and efficacy—has been partially validated by the initial SPY001 SKYLINE results.[7, 13, 15]
Investment Outlook:
The company's massive cash position of ~$1.2 billion de-risks the capital structure for the next 24-30 months, allowing management to focus purely on clinical execution.[17, 33] The upcoming readouts for SPY002 (TL1A) in mid-2026 and SPY003 (IL-23) in late 2026 serve as the primary short-to-medium-term catalysts.[4, 7] If these candidates match or exceed the performance of their rivals (Tulisokibart or Skyrizi), Spyre becomes a prime acquisition target for large pharma looking to replenish their biological pipelines.[20, 27]
Key Risks:
Investors must remain cognizant of the "therapeutic ceiling" and the possibility that combination therapy may not yield additive results in larger trials. Furthermore, the crowded nature of the TL1A market creates a scenario where clinical success may not translate directly to commercial dominance if Spyre is fourth or fifth to market.[16, 27]
SPECULATIVE GROWTH ASSET.
8. Technical Analysis, Price Action & Short-Term Outlook:
The current price action of SYRE is decidedly bullish, with the stock trading well above its 200-day moving average of $33.98 and its 50-day moving average of $45.28.[35, 38] Following the April 13, 2026, clinical update, the stock surged over 20% to reach a fresh 52-week high of $75.00.[47, 48] The short-term RSI of 83.66 indicates that the stock is currently overbought, suggesting a potential period of consolidation or a minor pullback to the $65 support level.[47, 48] Investors should monitor volume patterns following the closing of the upsized public offering to gauge institutional absorption of the newly issued shares.
OVERBOUGHT BULLISH MOMENTUM.
- Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million, https://ir.spyre.com/news-releases/news-release-details/spyre-therapeutics-inc-announces-closing-public-offering-and-0
- Pipeline | Spyre Therapeutics, https://www.spyre.com/pipeline
- SPY001 - Spyre Therapeutics, https://ir.spyre.com/static-files/c84b0fac-d3c3-4b1d-82dc-8f13f743c183
- Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2, https://ir.spyre.com/news-releases/news-release-details/spyre-therapeutics-poised-transformational-2026-six-expected
- Spyre Therapeutics Stock Forecast & Predictions: 1Y Price Target $85.08 | Buy or Sell NASDAQ: SYRE 2026 | WallStreetZen, https://www.wallstreetzen.com/stocks/us/nasdaq/syre/stock-forecast
- Spyre Therapeutics (SYRE) - Trefis, https://www.trefis.com/data/companies/SYRE
- Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients, https://ir.spyre.com/news-releases/news-release-details/spyre-announces-potential-best-class-spy001-part-induction
- Inflammatory Bowel Disease Treatment Market Share [2034] - Fortune Business Insights, https://www.fortunebusinessinsights.com/inflammatory-bowel-disease-treatment-market-106704
- TL1A Binder Market Size and Companies - DelveInsight, https://www.delveinsight.com/report-store/tl1a-binder-market-forecast
- Ulcerative Colitis Market Size, Share, Trends, Forecast – 2035 - Global Market Insights, https://www.gminsights.com/industry-analysis/ulcerative-colitis-market
- Crohn's Disease Treatment Market Size & Forecast, 2033 - Persistence Market Research, https://www.persistencemarketresearch.com/market-research/crohns-disease-treatment-market.asp
- SYRE Stock Forecast: Analyst Ratings, Predictions & Price Target 2026 - Public Investing, https://public.com/stocks/syre/forecast-price-target
- Spyre stock soars as UC drug touts Entyvio-rivalling potential - Clinical Trials Arena, https://www.clinicaltrialsarena.com/news/spyre-therapeutics-spy001-phase-ii-uc-skyline-topline-results/
- Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts, https://ir.spyre.com/news-releases/news-release-details/spyre-therapeutics-highlights-2025-priorities-and-robust
- Jefferies raises Spyre stock price target to $85 on trial data By ..., https://www.investing.com/news/analyst-ratings/jefferies-raises-spyre-stock-price-target-to-85-on-trial-data-93CH-4610974
- TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsight - PR Newswire, https://www.prnewswire.com/news-releases/tl1a-binder-market-set-to-expand-by-2034-with-key-players-such-as-merck-roche-teva-pharmaceuticals-sanofi-and-others-driving-multi-indication-advancements--delveinsight-302566777.html
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Thu, 02/19/2026, https://ir.spyre.com/news-releases/news-release-details/spyre-therapeutics-reports-fourth-quarter-and-full-year-2025
- TL1A inhibitors: 'Potentially transformative' option in inflammatory bowel disease - Healio, https://www.healio.com/news/gastroenterology/20250909/tl1a-inhibitors-potentially-transformative-option-in-inflammatory-bowel-disease
- Entyvio vs. Skyrizi for Crohn's Disease: Important Differences and Potential Risks. - GoodRx, https://www.goodrx.com/compare/entyvio-vs-skyrizi
- Mark McKenna - Spyre Therapeutics, https://www.spyre.com/people/mark-mckenna
- Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors - PR Newswire, https://www.prnewswire.com/news-releases/spyre-therapeutics-appoints-accomplished-biopharma-and-ibd-leader-mark-c-mckenna-former-chairman-president-and-ceo-of-prometheus-biosciences-to-its-board-of-directors-302052592.html
- Brian Connolly - Spyre Therapeutics, https://www.spyre.com/people/brian-connolly
- MiRa Huyghe - Spyre Therapeutics, https://www.spyre.com/people/mira-huyghe
- Ulcerative colitis trial shows strong SPY001 data for Spyre (NASDAQ: SYRE) - Stock Titan, https://www.stocktitan.net/sec-filings/SYRE/8-k-spyre-therapeutics-inc-reports-material-event-a15709780b44.html
- Inflammatory Bowel Disease Biologics Market | Global Industry Analysis & Outlook - 2036, https://www.factmr.com/report/inflammatory-bowel-disease-biologics-market
- Inflammatory Bowel Disease Treatment Market Size to Hit USD 32.46 Bn by 2035, https://www.precedenceresearch.com/inflammatory-bowel-disease-treatment-market
- Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data - Fierce Biotech, https://www.fiercebiotech.com/biotech/sanofi-points-long-term-efficacy-teva-partnered-ibd-drug-phase-2-extension
- Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis - PubMed, https://pubmed.ncbi.nlm.nih.gov/39321363/
- Roche 2026 Outlook: Navigating Post-Patent Cliff Growth & Pipeline Rejuvenation | SyneticX, https://www.syneticx.com/blog/roche.html
- Exploring the Potential of TL1A Inhibition in the Treatment of Inflammatory Bowel Disease Patients - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12853679/
- Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug, https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-and-Blackstone-Life-Sciences-Announce-400-Million-Strategic-Growth-Capital-Agreement-to-Advance-duvakitug/default.aspx
- 0001636282-26-000020 | 10-K | Spyre Therapeutics, https://ir.spyre.com/sec-filings/sec-filing/10-k/0001636282-26-000020
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Stock Titan, https://www.stocktitan.net/news/SYRE/spyre-therapeutics-reports-fourth-quarter-and-full-year-2025-j8m7ai19hi58.html
- Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month High - Should You Buy?, https://www.marketbeat.com/instant-alerts/spyre-therapeutics-nasdaqsyre-sets-new-12-month-high-should-you-buy-2026-04-13/
- Spyre Therapeutics (NASDAQ:SYRE) Sees Large Volume Increase on Analyst Upgrade, https://www.marketbeat.com/instant-alerts/spyre-therapeutics-nasdaqsyre-sees-large-volume-increase-on-analyst-upgrade-2026-04-15/
- Form 8-K for Spyre Therapeutics INC filed 04/16/2026, https://ir.spyre.com/static-files/b2c69949-3be9-451c-bd40-77e38485ad00
- Spyre Therapeutics, Inc. Stock Price: Quote, Forecast, Splits & News (SYRE) - Perplexity, https://www.perplexity.ai/finance/SYRE?comparing=SYRE,CMPS,PVLA,SMMT,VRTX,REGN
- Wall Street Zen Upgrades Spyre Therapeutics (NASDAQ:SYRE) to "Hold" - MarketBeat, https://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-spyre-therapeutics-nasdaqsyre-to-hold-2026-04-18/
- Spyre Therapeutics Announces Upcoming Report of SPY001 Part A Induction Topline Results from SKYLINE Trial on April 13, 2026 | Quiver Quantitative, https://www.quiverquant.com/news/Spyre+Therapeutics+Announces+Upcoming+Report+of+SPY001+Part+A+Induction+Topline+Results+from+SKYLINE+Trial+on+April+13%2C+2026
- Spyre Therapeutics Inc Stock Price Today | NASDAQ: SYRE Live - Investing.com, https://www.investing.com/equities/aeglea-bio-therapeutics-inc
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 AGA Evidence Synthesis - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/
- Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock | Tue, 04/14/2026 - 22:38, https://ir.spyre.com/news-releases/news-release-details/spyre-therapeutics-announces-pricing-upsized-4030-million-public
- Spyre Therapeutics, Inc. Insider Trading & Ownership Structure - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/ownership
- SYRE Spyre Therapeutics Forecast, Technical & Fundamental Analysis - Tickeron, https://tickeron.com/ticker/SYRE/forecasts-predictions/
- Spyre Therapeutics, Inc. (SYRE) Leadership & Management Team Analysis - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/management
- What is the current Price Target and Forecast for Spyre Therapeutics, Inc. (SYRE), https://www.zacks.com/stock/research/SYRE/price-target-stock-forecast
- SYRE Technical Analysis | Trend, Signals & Chart Patterns | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) | ChartMill.com, https://www.chartmill.com/stock/quote/SYRE/technical-analysis
- Spyre Therapeutics Stock Price Forecast. Should You Buy SYRE? - StockInvest.us, https://stockinvest.us/stock/SYRE